Healthcare
Bio-Techne Corporation (TECH)
Data as of July 13, 2026
Environment story
Bio-Techne demonstrates moderate environmental performance with transparent reporting and emerging commitments. The company has implemented a carbon accounting system and committed to science-based reduction targets by September 2026, addressing Scope 1, 2, and 3 emissions. However, the company currently lacks a disclosed net-zero target year, which triggers a 15-point deduction. The company maintains EcoVadis bronze medal status and has expanded to CDP climate assessment. No major environmental controversies or resource-extraction violations are documented. The company faces climate risks inherent to its California operations (earthquake, drought, wildfire) but has not disclosed specific operational decarbonization infrastructure investments. Greenwashing risk is moderate given the forward-looking nature of SBTi validation commitments without yet-finalized reduction targets.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Carbon Accounting System ImplementationExpanded data collection to include Scope 1, 2, and 3 emissions and consumption in fiscal 2025.Foundation for science-based target setting; enables comprehensive GHG footprint visibility.
-
Science-Based Targets Initiative (SBTi) CommitmentCommitted to validating Scope 1, 2, and 3 greenhouse gas reduction targets with SBTi by calendar year 2026.Positions company for credible, measurable emissions reductions aligned with climate science.
-
EcoVadis Sustainability AssessmentMaintained bronze medal rating; expanded scope to include CDP climate assessment in fiscal 2025.Third-party validation of sustainability practices; supports stakeholder confidence.
-
Double Materiality AssessmentFinalized assessment to identify financially material and stakeholder-relevant ESG impacts.Informs prioritization of sustainability strategy refinements and future EU/US regulatory compliance.
-
Climate Risk AssessmentOngoing assessment with external sustainability consultants to evaluate physical and transition climate risks.Supports resilience planning and strategic decision-making regarding operations in climate-vulnerable regions.
Social story
Bio-Techne demonstrates strong social performance with transparent workforce reporting, inclusive culture initiatives, and robust labor practices. The company reports 48% female workforce, 43% female managerial employees, 39% non-white workforce, and 28% non-white managerial representation. CEO-to-median-worker pay ratio is not disclosed, but executive compensation disclosures suggest moderation. No unionization of U.S. employees; international operations have government-mandated collective bargaining in certain jurisdictions. Turnover rates improved significantly in fiscal 2025. Eleven Employee Resource Groups support belonging and inclusion. The company has formalized diversity program, supplier diversity initiatives, and ERG oversight. No documented labor disputes, strikes, or NLRB complaints within 24 months. Supply-chain ethics practices are not comprehensively detailed in available documents. Engagement survey participation of 67% with 75% favorable feedback indicates strong employee satisfaction.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
EPIC Culture FrameworkCore values: Empowerment, Passion, Innovation, Collaboration. Annual employee recognition program rewards individuals and teams demonstrating EPIC values.Aligns workforce behavior with strategic objectives; fosters engagement and belonging.
-
Employee Resource Groups (ERGs)11 executive-sponsored ERGs operating globally as of June 30, 2025, offering mentorship, support, and engagement.Creates inclusive workplace environment; supports career development and sense of belonging.
-
Belonging InitiativeExecutive-sponsored program focused on welcoming working environment, continued education, broadened candidate pools, and sustained programs.Supports innovation and growth through diverse perspectives; improves talent attraction.
-
Expanded Stock Option and Equity ProgramsExtended stock option eligibility deeper into organization; expanded Long-Term Incentive program to include stock options and restricted stock units.Improves retention; aligns employee incentives with shareholder value creation across organizational levels.
-
Hybrid Work and Flexible ArrangementsEmpowered work/life integration through hybrid work models wherever feasible in fiscal 2025.Improves employee satisfaction and retention; addresses post-pandemic workforce expectations.
-
Parental Leave ExpansionExpanded parental leave program in recent years.Supports work-life balance and retention of critical talent.
-
Learning and Development InvestmentComprehensive global Learning and Development program delivering compliance, soft skills, technical, business, and interpersonal training; support for external education.Develops talent pipeline; reduces need for external recruitment; supports M&A integration.
-
Safety and Well-Being ProgramsFoundational safety training for all employees; enhanced hazard awareness training by role; mental health benefit coverage; crisis management protocols.Protects employee physical and psychological health; supports operational continuity.
-
Volunteer Time OffU.S. employees receive paid day off to participate in local community volunteering.Strengthens community relationships; supports employee engagement and social responsibility.
Governance story
Bio-Techne demonstrates robust governance with strong board independence, transparent practices, and effective oversight mechanisms. Board composition is 89% independent (8 of 9 directors) with supermajority independence exceeding the 75% threshold. No dual-class voting structure exists; shareholders have annual director election rights and proxy access. Board Chair and CEO roles are separated, with an independent Chair (Robert V. Baumgartner) and CEO (Kim Kelderman). All four standing committees consist entirely of independent directors. The company has formalized board refreshment policies, overboarding limits, mandatory retirement at age 75 (with waiver provisions), and annual board/committee evaluations. No lobbying expenditures targeting environmental deregulation or consumer-protection rollbacks are disclosed. The company reports zero political contributions in fiscal 2025 and maintains Board sole authority over any political spending. No material antitrust proceedings, SEC consent decrees, or privacy fines are documented. The company has implemented clawback policies, executive stock ownership requirements, and hedging/pledging prohibitions. Board-level oversight of cybersecurity, AI, and ESG risks is demonstrated through committee assignments and regular management reporting.
Criticisms on file
No material criticisms on file for this pillar.
Disclosed initiatives
-
Board Independence and Leadership Separation89% independent board (8 of 9); separated Chair (independent) and CEO roles; 100% independent committee composition.Ensures rigorous independent oversight of management; reduces conflicts of interest.
-
Board Refreshment PolicyMandatory retirement at age 75 (subject to waiver if in Company's best interests); 18-month process for identifying successors; 44% of independent directors appointed since 2019.Ensures predictable, steady infusion of fresh perspectives; retains institutional knowledge through overlapping tenures.
-
Diversity and Skills-Based Director RecruitmentPrinciples of Corporate Governance codify commitment to diverse range of deeply qualified professionals; external board search firm engagement.Broadens viewpoints; improves decision-making quality; enhances stakeholder legitimacy.
-
Comprehensive Board Evaluation ProgramAnnual Board and committee self-evaluations; assessment by Nominations and Governance Committee; feedback-driven improvements.Identifies performance gaps; drives continuous governance improvements.
-
Overboarding LimitsIndependent directors limited to four other public company board seats; enforced Nasdaq compliance.Ensures adequate director attention and availability for Company matters.
-
Executive Stock Ownership RequirementsExecutives and directors required to own meaningful amount of Bio-Techne common stock.Aligns leadership interests with long-term shareholder value; reduces short-term incentive distortions.
-
Hedging and Pledging ProhibitionExecutive officers and directors prohibited from hedging or pledging Company stock.Prevents risk-shifting behavior; ensures alignment with shareholder interests.
-
Clawback PolicyFormal clawback policy and clawback provisions in equity award agreements.Enforces accountability for executive performance; protects shareholder value in case of misconduct or restatements.
-
Risk Oversight FrameworkBoard-level oversight of material enterprise risks including cybersecurity, AI, compliance, privacy, environmental, and ESG matters; regular management reporting throughout fiscal year.Anticipates and mitigates systemic risks; supports long-term resilience.
-
Shareholder Rights and Proxy AccessAnnual director elections; majority voting with resignation policy for under-supported directors; proxy access bylaw; right to call special meeting; single voting class.Empowers shareholders to influence governance; maintains accountability mechanisms.
-
Political Contribution ControlsBoard sole and exclusive authority to approve political contributions; zero contributions in fiscal 2025; Company characterizes mission as apolitical.Prevents misalignment of corporate resources with shareholder interests; maintains governance discipline.
-
Executive Compensation Philosophy EvaluationCompensation Committee undertook rigorous re-evaluation of compensation program design in response to shareholder feedback; bench testing of enterprise performance metrics planned for FY26.Ensures compensation aligns with long-term value creation; incorporates shareholder input.
-
Artificial Intelligence Oversight AssignmentBoard formally assigned oversight of AI applications, use, and risks to Science and Technology Committee in fiscal 2025.Ensures governance of emerging, high-impact technology; anticipates regulatory and operational risks.
-
Director Onboarding and Continuing EducationComprehensive orientation including business strategy, financial/accounting/risk issues, ethics/compliance, facility tours, executive meetings; on-demand accredited virtual training on AI, sustainability, governance.Accelerates director effectiveness; maintains governance expertise currency.
These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Bio-Techne Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Bio-Techne Corporation in the app for interactive charts and portfolio building.
Browse Companies · Methodology · Terms of Service · Privacy Policy · Back to Missionomics